[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates a loss for the first half of 2025, with net profit attributable to owners of the parent company projected to be between -9.0 million RMB and -6.3 million RMB Estimated Performance Indicators | Performance Indicators | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Owners of the Parent Company | -9.0 million to -6.3 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | -8.72 million to -6.02 million | [Prior Period Operating Performance and Financial Position](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) Contrary to the current period's projected loss, the company achieved profitability in the prior period (first half of 2024), with net profit attributable to owners of the parent company at 22.5219 million RMB Prior Period Performance Indicators | Performance Indicators | Amount (RMB) | | :--- | :--- | | Total Profit | 31.2322 million | | Net Profit Attributable to Owners of the Parent Company | 22.5219 million | | Net Profit Attributable to Owners of the Parent Company After Deducting Non-Recurring Gains and Losses | 20.7641 million | | Earnings Per Share | 0.06 RMB/share | [Primary Reasons for Current Period's Projected Loss](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E4%BA%8F%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The current period's projected loss is primarily due to declining sales revenue and gross profit, increased R&D and market investment, exchange losses, and a slower reduction in expenses - Sales revenue and gross profit simultaneously declined due to the domestic macroeconomic environment and policies such as centralized procurement price reductions, leading to lower hospital client purchase prices and reduced order volumes[8](index=8&type=chunk) - To adapt to market changes, the company adjusted its business layout, continuously investing resources in the iterative R&D, production, and market development of its proprietary "ACME" product[8](index=8&type=chunk) - The appreciation of the New Taiwan Dollar resulted in exchange losses for the company, negatively impacting net profit[8](index=8&type=chunk) - Despite implementing expense controls, the short-term decrease in administrative and selling expenses was less than the reduction in revenue, contributing to the performance decline[8](index=8&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company explicitly states that this performance forecast data is a preliminary calculation and has not been audited, with the final accurate financial data to be released in the official 2025 semi-annual report - This performance forecast has not been audited by a certified public accountant, and the final accurate data will be based on the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)[10](index=10&type=chunk)

合富中国（603122）公告，预计2025年半年度归属于母公司所有者的净利润为-900万元到-630万元，与 上年同期相比，将出现亏损。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益后的净利 润为-872万元到-602万元。 ...

合富（中国）医疗科技股份有限公司董事会 2025 年 7 月 11 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-6 月合并营业收入人民币 36,765.82 万元，较去年同期下降 23.53%，2025 年 1-5 月合并营业收入较去年同期下降 24.15%，下降幅度收窄 0.62%，营收情况持续改善。 特此公告。 证券代码：60312 ...

Core Viewpoint - 合富中国 reported a consolidated revenue of 368 million yuan for the first half of 2025, representing a year-on-year decline of 23.53% [1] Revenue Performance - The revenue for the first five months of 2025 showed a year-on-year decline of 24.15%, indicating a slight improvement in the revenue trend as the decline narrowed by 0.62% [1]

Core Points - The stock price of HeFu China (603122) increased by 2.07% to 6.89 CNY as of July 4, 2025, with a market capitalization of 2.743 billion CNY [1] - The company completed the cancellation of its initial public offering (IPO) fundraising account, with a total fundraising amount of 416.96 million CNY and a net amount of 359.69 million CNY after expenses [1][2] - HeFu China announced a cash dividend of 0.13 CNY per share for the 2024 annual equity distribution, totaling 51.75 million CNY [3] Company Announcements - HeFu China has completed the cancellation of its IPO fundraising account, with the balance of 58.45 million CNY transferred to the general account [2] - The company signed a tripartite supervision agreement regarding the fundraising account and later terminated it after the account's cancellation [2] - The cash dividend distribution was approved at the annual shareholders' meeting on June 25, 2025, with specific tax implications for different types of shareholders [3]

Core Viewpoint - The company has completed the cancellation of its fundraising special accounts, following the approval of its fundraising management and usage protocols, ensuring compliance with regulatory requirements [1][2][3]. Fundraising Basic Information - The company raised a total of RMB 416,960,308.00 through its initial public offering of 99,513,200 shares at a price of RMB 4.19 per share, with all funds received by February 11, 2022 [1]. Fundraising Management and Storage - The company established a fundraising management system to ensure proper storage and usage of the raised funds, signing a tripartite supervision agreement with relevant banks and its sponsor [2]. - A quadripartite supervision agreement was later signed to allow the company to provide loans to its wholly-owned subsidiary for project implementation [2]. Fundraising Account Cancellation - The company decided to open a new special account for fundraising to improve the yield of the raised funds and subsequently canceled the previous accounts, with the cancellation process completed by March 11, 2025 [3][4]. - The total balance of the canceled fundraising accounts was transferred to the new account, and all relevant agreements were terminated [4].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-029 合富（中国）医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.13元 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/11 | － | 2025/7/14 | 2025/7/14 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 25 日的2024年年度股东会审议通过。 本次利润分配以方案实施前的公司总股本398,052,633股为基数，每股派发现金红利0.13 元（含税），共计 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-030 合富（中国）医疗科技股份有限公司 关于募集资金专户完成销户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司本次注销的募集资金专户信息如下： 二、募集资金存放和管理情况 为规范公司募集资金管理和使用，保护投资者权益，按照《中华人民共和国 公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》和《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等有关法律、法规和规范性文 件的规定，结合公司实际情况，公司已制定了《募集资金管理制度》，对募集资 金实行专户存储制度，对募集资金的存放、使用、项目实施管理、投资项目的变 更及使用情况的监督进行了规定。公司于 2022 年 2 月与保荐机构海通证券股份 有限公司、存放募集资金的上海银行虹桥路支行、兴业银行股份有限公司上海分 1 行营业部、富邦华一银行有限公司上海徐汇支行、招商银行股份有限公司上海分 行营业部分别签署 ...

Group 1 - The first meeting of the third board of directors of Hefei (China) Medical Technology Co., Ltd. was held on June 25, 2025, with all six directors present, and the meeting was conducted legally and effectively [1] - Li Jun was elected as the chairman of the third board of directors, with a term lasting until the end of the current board's term [1][2] - The board approved the election of various specialized committees, with Li Jun serving as the chairman of the Strategy and ESG Committee [2] Group 2 - Wang Qiongzhi was appointed as the general manager, with a term lasting until the end of the current board's term [3] - The board also appointed Zeng Guankai, Wang Fenghua, and Chen Ye as vice general managers, and Wang Qiongzhi as the financial supervisor [3][4] - Zhu Ying was appointed as the board secretary, and Xu Jiayuan was appointed as the securities affairs representative, both with terms until the end of the current board's term [3][4]

Core Viewpoint - The legal opinion letter issued by Beijing Global Law Firm Shanghai Branch confirms that the 2024 Annual General Meeting of Shareholders of HeFu (China) Medical Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting procedures and voting results [1][3][22]. Group 1: Meeting Procedures - The annual general meeting was held on June 25, 2025, with the notice published on June 5, 2025, meeting the requirement of a 20-day advance notice [3][5]. - The meeting was conducted at the specified location, and both on-site and online voting options were provided to shareholders [5][6]. Group 2: Qualifications of Participants - The second board of directors of HeFu China convened a meeting on June 4, 2025, to propose the annual general meeting, confirming the board as the convener [5][6]. - A total of 3 shareholders and their proxies attended the meeting, representing 792,224 shares, which is 0.1990% of the total voting shares [5][6]. Group 3: Proposals and Voting Procedures - No additional proposals were made beyond those listed in the meeting notice, and all proposals were voted on as stated [6][22]. - The voting process combined both on-site and online methods, with shareholders required to choose one voting method [7][22]. Group 4: Voting Results - The voting results for various proposals showed overwhelming support, with the majority receiving over 99% approval [8][9][10][11][12][13][14][15][16][17][18][19][20][21]. - Specific proposals included the annual board work report, independent director's report, and financial statements, all of which received high approval rates [8][9][10][11][12][19].